Logo

Thermo Fisher to Supply Genentech with RNAi Tech for Drug Studies

Nov 04, 2008
NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will supply Genentech with RNAi technology for use in siRNA-based drug discovery research.
 
Under the agreement, Thermo Fisher Scientific will provide Genentech with siRNA design, stabilization, delivery, and related RNAi technologies from its RNAi Discovery and Therapeutic Services lab in Colorado.
 
The drugs Genentech is working on would silence expression of disease-related genes, which could help extend drug research efforts on targets that have so far not been successfully developed.
 
“Our work with Genentech will focus on developments that will enable in vivo target validation and potentially human therapeutic applications of RNAi technology,” Thermo Fisher Scientific VP of Global R&D Ian Jardine said in a statement.
 
Financial terms of the agreement were not released.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.